for the Agence Nationale de Recherches sur le Sida (ANRS) 1220 Primo-CI Study Group Background: WHO recommends initiating combination antiretroviral treatment at the minimal CD4 cell threshold of 350 cells/ml. In sub-Saharan Africa, the time for a recently infected patient to reach this threshold is unclear.
Introduction
In sub-Saharan Africa, 3 910 000 adults have started combination antiretroviral therapy (ART) within the past 5 years [1] . Despite this unprecedented scaling-up, patients started ART with a mean CD4 cell count between 100 and 150 cells/ml [2] [3] [4] [5] . In 2010, the WHO guidelines recommended initiating ART when the CD4 cell count drops below 350 cells/ml [6] . Little is known about the annual number of HIV-infected individuals who reach the CD4 cell threshold for ART initiation. Estimates of the probability of reaching this threshold in a Programme PAC-CI, Abidjan, Cô te d'Ivoire, b Inserm U897, c Université Victor Segalen Bordeaux 2, ISPED, Bordeaux, France, and d CeDReS Laboratory, University Hospital of Treichville, Abidjan, Cô te d'Ivoire. Correspondence to Dr Albert K. Minga individuals who were diagnosed early would help modellers and drug providers anticipate the need for antiretroviral drugs. Moreover, estimates of the time spent by patients who, with a CD4 cell count above the threshold, are, thus, unlikely to receive ART may contribute to the knowledge of the risk of HIV transmission [4] .
We estimated the probability of reaching different CD4 cell thresholds over time in a cohort of HIV-1 adults who recently seroconverted in Abidjan, Côte d'Ivoire.
Methods

Study population
The Agence Nationale de Recherches sur le Sida (ANRS) 1220 Primo-CI cohort of seroconverters has been previously described [7] . Since 1997, blood donors at the National Blood Bank (centre national de transfusion sanguine, CNTS) in Abidjan, Cote d'Ivoire who were tested HIV-1 positive were offered to be included in the cohort if the time since their estimated date of seroconversion was less than 36 months. The estimated date of seroconversion was the midpoint between the last negative and the first positive HIV-1 test. Once included in the cohort, people benefited from a standardized follow-up, which includes a CD4 cell count every 6 months (FACScan then FACSCalibur; Becton Dickinson, Aalst-Erembodegem, Belgium). ART was given to patients who fulfilled ART initiation criteria according to WHO guidelines.
Statistical analysis
We modelled the CD4 cell decline on the individual level using a linear mixed model with two slopes (before and after 6 months), adjusted for the delay since the estimated date of seroconversion (<6, 6-12 and >12 months), the baseline plasma HIV-1-RNA level (4.5 vs. >4.5 log 10copies/ml), the baseline CD4 cell count (<350, 350-500, >500 cells/ml), mortality and ART initiation during follow-up. The model was validated by confirming that the simulated CD4 cell evolution fit the actual CD4 cell evolution in the cohort (Fig. 1) . The probabilities over time of having a CD4 cell count below 500 and 350 cells/ml were estimated by the Kaplan-Meier method. The robustness of the results was studied in sensitivity analysis by estimating the probability of the first event among the following: death, loss to follow-up, ART initiation or first CD4 cell count below the threshold. (IQR: 3.9-5.0); only 11 patients (4%) had a plasma HIV-1-RNA level below the detectability threshold (300 copies/ml), all had CD4 cell count less than 500 cells/ml. All but two of the participants were classified as infected through heterosexual contact. At enrolment, 289 patients (95%) were classified as clinical stage A according to 1993 Centers for Disease Control and Prevention (CDC) classification, 13 as CDC stage B and two as CDC stage C. There was a significant difference between men and women in terms of age (men: median 31 years, IQR: 27-37; women: median 27 years, IQR: 24-32; P ¼ 0.002), time since seroconversion (men: median 8 months, IQR: 4-19; women: median 11 months, IQR: 6-19; P ¼ 0.001), plasma HIV-1-RNA level (men: median 4.70 log 10 copies/ml, IQR: 4.00-5.10; women: 4.25 log 10 copies/ml, IQR: 3.80-4.82; P ¼ 0.02). Baseline CD4 cell count was not significantly different between sexes.
Results
The median follow-up time in the cohort was 5.4 years (IQR: 4.0-8.6). The probability of having a CD4 cell count less than 350 cells/ml was 0.29, 0.40, 0.55 and 0.67 at study entry, 2, 4 and 6 years, respectively (Fig. 2a ).
The probability of having a CD4 cell count less than 500 cells/ml was 0.57, 0.72, 0.79 and 0.84 at study entry, 2, 4 and 6 years, respectively (Fig. 2b) . These findings did not change significantly when considering the outcomes of death, loss to follow-up, initiation of ARTor first CD4 cell count below the threshold ( Fig. 2a and b) . The time for 75% of the patients to reach the threshold was 3 years for 500 cells/ml and 7 years for 350 cells/ml.
Discussion
In this cohort, almost one-third of recent seroconverters had a CD4 cell count below the current ART eligibility threshold at first contact, about 6% more crossed it each year and 25% still remained above this threshold until 7 years. If the threshold was raised to 500 cells/ml, 57% patients would be immediately eligible, whereas 14% would remain above the threshold at 7 years.
In our study, the median time between the last negative and first positive HIV test was 8 months, and the median delay between seroconversion and enrolment was 9 months. In a study in Thailand, 17% of IDUs had a CD4 cell count of less than 350 cells/ml after a similar time since seroconversion [8] , whereas 65% of blood donors enrolled in another study within 2 years after seroconversion had a baseline CD4 cell count of less than 500 cells/ml [9] . In the Cascade cohort of seroconverters from high-income countries, 27% reached the 350 cells/ml CD4 cell threshold 1 year after seroconversion and 55% after 5 years [10] . Thus, the time to first CD4 cell count of less than 350 cells/ml seems shorter in our population compared with Europe and with IDUs in Thailand, but close to that reported from blood donors in Thailand. Our population of blood donors includes a high proportion of men and may not be entirely representative of the overall population of HIVinfected adults in Côte d'Ivoire who are predominantly women [11] .
Different methods have been proposed to estimate the date of seroconversion. In this cohort, we used the midpoint between last negative and first positive test, a method commonly used by others [12] [13] [14] [15] [16] . Alternative methods, including Weibull analysis, lead to similar estimates [17] . In this study, however, we used the date of first contact with care as time 0, rather than the date of seroconversion. Contrary to the latter, the date of entry into care is accurately known and can been used as a landmark by policy makers. We wanted entry into care to be as close as possible to seroconversion, although also being something that could be reached in the real life. Enrolment in a seroconverter cohort represents the earliest entry into care that could be reached in programs offering HIV testing on a pluri-annual basis.
Our findings have two practical implications. First, the high proportion of individuals whose CD4 cell count was already below the current threshold for ART strongly suggests that efforts should be made to diagnose HIV infection as soon as possible after seroconversion. This requires implementation of HIV testing in the general population much more frequently than it is currently done [2] , and even more so if guidelines continue to move toward higher CD4 cell thresholds for ART initiation [18] .
Second, even if the CD4 cell threshold for treatment was raised to 500 cells/ml, a minority, but still significant proportion of patients, would remain untreated for many years. Knowing who these patients are and how they participate in HIV transmission would be critical in the current debate considering ART as a prevention tool [4] .
Conclusion
Almost one-third of recent seroconverters had a CD4 cell count below the current ART eligibility threshold at first contact, about 6% more crossed it each subsequent year and 25% remained above this threshold after 7 years. If the threshold was raised to 500 cells/ml, 57% of recent seroconverters would immediately be eligible, whereas 14% would remain above the threshold at 7 years. These results should help modellers and treatment providers anticipate the need in antiretroviral drugs.
